http://lifesciencedigest.com/2009/11/29/biotech-baker%e2%80%99s-dozen-to-watch-at-hematology-meeting/ MD Becker Partners' newsletter covering the life science industry Thu, 29 Mar 2012 11:37:43 +0000 hourly 1 http://wordpress.org/?v=3.3.1 http://lifesciencedigest.com/2009/11/29/biotech-baker%e2%80%99s-dozen-to-watch-at-hematology-meeting/comment-page-1/#comment-155 Buyout Buzz at ASH Hematology Confab : Beck on Biotech Mon, 07 Dec 2009 15:24:22 +0000 http://mdbpartners.com/blog/?p=499#comment-155 [...] companies announcing upcoming clinical data presentations at ASH [as of November 27, 2009] and from our recent article and identified three small-cap [eg, market capitalization less than $1 billion] biotechnology [...] [...] companies announcing upcoming clinical data presentations at ASH [as of November 27, 2009] and from our recent article and identified three small-cap [eg, market capitalization less than $1 billion] biotechnology [...]

]]> http://lifesciencedigest.com/2009/11/29/biotech-baker%e2%80%99s-dozen-to-watch-at-hematology-meeting/comment-page-1/#comment-154 w clementi Tue, 01 Dec 2009 22:19:44 +0000 http://mdbpartners.com/blog/?p=499#comment-154 Good article and interesting approach to learning about emerging therapies. However, most of the abstracts are describing studies that are 1) a year to 18 months old and 2) are not predictive of clinical or regulatory success. It would be interesting to group the abstracts by disease and then list the number of agents in each group. After a quick glance, it seems like multiple myeloma and lymphomas have the most candidates. In this way, one could assess who is "winning" this very early race. Good article and interesting approach to learning about emerging therapies. However, most of the abstracts are describing studies that are 1) a year to 18 months old and 2) are not predictive of clinical or regulatory success. It would be interesting to group the abstracts by disease and then list the number of agents in each group. After a quick glance, it seems like multiple myeloma and lymphomas have the most candidates. In this way, one could assess who is “winning” this very early race.

]]>